Binx point-of-care STI testing clears FDA

By staff writers

August 12, 2019 -- Binx Health's point-of-care binx io molecular diagnostic instrument enabling rapid testing and reporting of chlamydia and gonorrhea infections in women is now cleared by the U.S. Food and Drug Administration (FDA).

The polymerase chain reaction (PCR) product includes a benchtop instrument with a single-use, assay-specific cartridge. Vaginal swabs may be collected by patients in a clinical setting or by laboratorians, and results are available within half an hour, according to the company.

Binx Health
Binx Health's binx io molecular diagnostic instrument. Image courtesy of Binx Health.

The hope is that providing results while patients are in the office will help those who test positive for a sexually transmitted infection (STI) receive treatment, rather than patients slipping through the cracks after a delay in reporting, which is common in clinical practice.

The FDA clearance was supported by a trial of more than 1,500 female patients, in which testing had 96.1% sensitivity and 99.1% specificity for chlamydia and 100% sensitivity and 99.9% specificity for gonorrhea, the company noted.

Will new HIV recommendations boost test volume?
New recommendations released June 11 from the U.S. Preventive Services Task Force continue to strongly advise HIV screening for adolescents and adults,...
SpeeDx gonorrhea test gets breakthrough status in U.S.
The ResistancePlus GC test from SpeeDx for detecting Neisseria gonorrhoeae bacteria has received breakthrough device designation from the U.S....
STD test market grows with incidence, new tech
The need to make screening and testing of sexually transmitted diseases (STDs) more accessible worldwide is creating opportunities for manufacturers of...
FDA gives nod to Hologic assay for STI bacterium
The U.S. Food and Drug Administration (FDA) has allowed the marketing of a new assay by Hologic for detecting Mycoplasma genitalium, a type of...

Copyright © 2019

Last Updated np 10/2/2019 5:10:55 PM